Haleon PLC Sponsored ADR (NYSE:HLN) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Haleon a “Moderate Buy” consensus: Of 11 analysts covering the stock, three rate it a buy, two a strong buy, five a hold and one a sell. Recent recommendations include Jefferies’ “buy” and Morgan Stanley’s “overweight,” offset by a Rothschild & Co Redburn downgrade to “hold.”
• Haleon shares opened at $9.94, down 1.3%, with a market capitalization of approximately $43.7 billion. The stock has traded between $8.65 and $11.28 over the past year.
• The company declared a quarterly dividend of $0.0642 per share, payable September 17 to shareholders of record August 14. Hedge funds and other institutional investors own 6.67% of Haleon, with several smaller institutions recently increasing their positions.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, three have issued a buy rating and two have given a strong buy rating to the company.

A number of brokerages have issued reports on HLN. Rothschild & Co Redburn downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 16th. Royal Bank Of Canada restated a "sector perform" rating on shares of Haleon in a research report on Tuesday, August 11th. Zacks Research raised Haleon from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 19th. Morgan Stanley reiterated an "overweight" rating on shares of Haleon in a research report on Thursday, August 6th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Haleon in a research note on Monday, August 24th.

Haleon Trading Down 1.3%

Shares of HLN opened at $9.94 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. The company has a 50 day simple moving average of $9.86 and a two-hundred day simple moving average of $9.77. Haleon has a 1 year low of $8.65 and a 1 year high of $11.28. The firm has a market cap of $43.70 billion, a P/E ratio of 25.47, a price-to-earnings-growth ratio of 2.24 and a beta of 0.12.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.0642 per share. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon's dividend payout ratio is 30.77%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HLN. Parkside Financial Bank & Trust raised its stake in Haleon by 101.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company's stock valued at $29,000 after purchasing an additional 1,433 shares in the last quarter. Western Wealth Management LLC purchased a new position in shares of Haleon in the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company's stock worth $30,000 after buying an additional 2,404 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company's stock worth $50,000 after buying an additional 1,203 shares during the last quarter. Finally, Atlantic Union Bankshares Corp raised its position in shares of Haleon by 69.4% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company's stock valued at $63,000 after buying an additional 2,567 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source